Nolomirole

Nolomirole
Clinical data
Other names	CHF-1035; CHF1035; 5,6-Diisobutyryloxy-N-methyl-2-aminotetralin; 5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalene; 5,6,7,8-Tetrahydro-6-(methylamino)-1,2-naphthylene diisobutyrate; N-Methyl-2-aminotetralin
Routes of; administration	Oral
Drug class	Dopamine D2 receptor agonist; α2-Adrenergic receptor agonist
ATC code	None;
Identifiers
	IUPAC name [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;
CAS Number	90060-42-7;
PubChem CID	216238;
ChemSpider	187439;
UNII	6EMF80C55F;
ChEMBL	ChEMBL2105142;
CompTox Dashboard (EPA)	DTXSID10869044 ;
Chemical and physical data
Formula	C19H27NO4
Molar mass	333.428 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C(=O)OC1=C(C2=C(CC(CC2)NC)C=C1)OC(=O)C(C)C;
	InChI InChI=1S/C19H27NO4/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4/h6,9,11-12,14,20H,7-8,10H2,1-5H3; Key:OMMYLOLVPCCZQZ-UHFFFAOYSA-N;

Nolomirole (INNTooltip International Nonproprietary Name; developmental code name CHF-1035), also known as 5,6-diisobutyryloxy-N-methyl-2-aminotetralin, is a dual dopamine D₂ and α₂-adrenergic receptor agonist which was under development for the treatment of heart failure but was never marketed. It is taken orally.